Browsing Tag
Circulating tumor DNA
2 posts
I-SPY 2 data puts Natera’s Signatera at the center of early breast cancer risk debates
Natera’s I-SPY 2 data suggests ctDNA may finally align early breast cancer risk with treatment intensity. Read why this matters for payers and markets.
Natera boosts ctDNA and lymphoma detection capabilities through Foresight Diagnostics acquisition
Find out how Natera’s acquisition of Foresight Diagnostics could redefine ultra-sensitive cancer detection and reshape the future of MRD testing.